Semaglutide 2.4 mg (Wegovy) received FDA approval for adolescents 12 and older in December 2022 [11]
Semaglutide, by contrast, offers: Faster and more significant weight loss Comprehensive benefits for individuals with or without diabetes Established safety and effectiveness in large-scale clinical trials If achieving substantial weight loss is your primary goal, Semaglutide is likely the better choice
By keeping peptide production closer to home, we can better control product standards, reduce reliance on uncertain imported inventory, and provide Canadian researchers with a more transparent and reliable source for research peptides
The rodent data are important background, but they represent the beginning of an evidence chain, not the end of one
PARPs: Enzymes that help repair DNA damage, but use up large amounts of NAD+ in the process